Skip to content

    Epigral

    EPIGRAL
    Chemicals·10 Nov 2025
    Management Summary

    Epigral reported a challenging Q2 FY26 with revenue declining 4% QoQ to ₹589 crores and EBITDA dropping 19% QoQ to ₹132 crores, primarily due to lower realizations in products like CPVC and hydrogen peroxide, and subdued plant utilization. Despite H1 headwinds, the company maintains a healthy EBITDA margin of 25% and significantly improved its net debt to EBITDA ratio to 0.8x. Management expects a stronger H2 FY26 with anticipated volume growth, improved utilization, and upcoming revenue contributions from new projects like Chlorotoluene, while also progressing on future CAPEX plans for diversification and import substitution.

    Highlights

    5
    • Net debt to EBITDA improved to 0.8x as of September 30, 2025, from 1.4x a year ago, indicating a comfortable debt position.

    • Strong cash flow from operations covered the H1 FY26 CAPEX of ₹236 crores.

    • CAPEX projects for CPVC, Epichlorohydrin, and power plants are on schedule for commissioning within budget and timeline.

    • Company is progressing with new project announcements for both current complex and new land, targeting import substitution products with double-digit growth potential beyond FY2028.

    • Anticipated volume growth and improved plant utilization in H2 FY26, with early signs of demand recovery post-monsoon and maintenance.

    Concerns

    4
    • Q2 FY26 revenue declined by 4% QoQ to ₹589 crores and EBITDA dropped 19% QoQ to ₹132 crores, primarily due to reduced realizations and lower plant utilization.

    • H1 FY26 revenue declined by 6% YoY to ₹1,204 crores, and EBITDA margin compressed to 25% from 28% in H1 FY25.

    • CPVC prices dropped by approximately 10% QoQ in Q2 FY26, and capacity utilization for CPVC was around 50% in Q1 and Q2 FY26.

    • Chlorotoluene value chain, commissioned in March 2025, incurred basic expenses, depreciation, and interest costs in H1 FY26 without contributing to top-line or bottom-line.

    What Changed1

    vs Q3 FY26

    Guidance items7 → 8 (+1)
    Key financials

    Metrics

    9

    Periods

    2

    Headline

    8
    • Revenue
      ₹589 Cr
      QoQ-4%
    • EBITDA
      ₹132 Cr
      QoQ-19%
    • PAT
      ₹51 Cr
    • H1 FY26 Revenue
      ₹1,204 Cr
      YoY-6%
    • H1 FY26 EBITDA Margin
      25%

    Q2 FY26

    1
    • Plant Utilization
      78%

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Net ₹496 crores · 0.8x EBITDA

    Liquidity

    Liquidity disclosed

    Strong cash flow from operations are good enough for the CAPEX that we had to spend.

    Guidance & targets

    8
    CategoryTargetPriority
    Volume Growth
    Volume Growth
    volume growth
    Medium
    Plant Utilization
    Plant Utilization
    better utilization levels
    Medium
    Revenue Contribution
    Derivative and Specialty Business Revenue Contribution
    70%
    High
    New Project Announcement
    New Project Announcement
    soon
    High
    New Project Growth
    Growth from New Project
    sizable to drive growth
    High
    Interest Expense
    Interest Expense
    ₹45-50 crores
    High
    Chlorotoluene Revenue Contribution
    Sizable Revenue Contribution from Chlorotoluene
    start
    High
    New CAPEX Announcement
    New CAPEX Announcement
    this year
    High

    H2 FY26 Volume Growth

    H2 FY26
    CurrentMarginal 2% QoQ growth in Q2 FY26
    TargetVolume growth in H2 FY26

    Why it matters

    Volume growth is a key indicator of demand recovery and overall business performance, especially after a subdued H1.

    and we anticipate volume growth in H2 FY 26, positioning the second half for the stronger performance compared to H1.

    How to verify

    key_financials.metrics[label='Volume Growth']

    Risks & concerns

    4
    RiskSeverity

    Geopolitical Uncertainty

    Persistent geopolitical uncertainty impacting the chemical market.Management acknowledged

    medium

    Seasonal Demand and Slower Recovery

    Slower recovery attributed to early and prolonged monsoon season and subdued demand.Management acknowledged

    low

    Subdued Demand and Lower Capacity Utilization

    Subdued demand and lower capacity utilization impacted H1 FY26 performance.Management acknowledged

    medium

    Price Volatility and Return on Capital for New CAPEX

    Concern that overcapacity and low prices could lead to low return on capital for new investments, given prices are not under company's control.Analyst acknowledged

    medium

    Q&A highlights

    8

    “But as of now, we believe that the majority of the people in India is converting more and more to the resin rather than in the compound. So, they prefer to buy a resin rather than the compound buying from the market.”

    Clarifies Epigral's focus on CPVC resin production, catering to customers who prefer to do in-house compounding, and explains why resin capacity expansion is prioritized over compound capacity.

    asked by Nipun Sharma

    2 min read6 chapters

    Detailed Narrative

    01

    Q2 FY26 Performance Overview

    Epigral reported a challenging Q2 FY26, with sales volume showing a marginal 2% QoQ growth, but revenue declined by 4% QoQ to ₹589 crores due to reduced realizations in certain product categories. EBITDA saw a significant drop of 19% QoQ to ₹132 crores, resulting in a Profit After Tax of ₹51 crores. The company attributed this performance to an extended monsoon, subdued demand, and ongoing plant maintenance work.

    02

    H1 FY26 Financials and Margin Compression

    For the first half of FY26, plant utilization stood at 75%, a decrease from 83% in H1 FY25, leading to a 6% YoY decline in revenue to ₹1,204 crores. The EBITDA margin for H1 FY26 compressed to 25% from 28% in H1 FY25. This margin contraction was primarily due to lower realizations for several products and reduced utilization levels, impacting overall profitability.

    03

    Debt Management and Capital Efficiency

    Epigral demonstrated strong debt management, with its net debt to EBITDA ratio improving significantly to 0.8x as of September 30, 2025, compared to 1.4x a year prior. Net debt remained relatively flat at ₹496 crores. The company's ROCE stood at 21% including capital work in progress, and 24% excluding it, indicating efficient capital deployment despite the current market conditions. Strong cash flow from operations adequately funded the H1 FY26 CAPEX of ₹236 crores.

    04

    CAPEX Projects and Diversification Strategy

    The company's ongoing CAPEX projects, including doubling capacity for CPVC and Epichlorohydrin, and establishing 19.8 MW wind/solar hybrid power plants, are progressing on schedule and within budget. These expansions are expected to increase revenue contribution from derivative and specialty businesses to 70%. Additionally, Epigral is advancing plans for two new projects, one at the current complex and another greenfield site, targeting import substitution products for long-term growth beyond FY2028.

    05

    Chlorotoluene Value Chain and Future Growth Drivers

    The Chlorotoluene value chain, commissioned in March 2025, is currently incurring basic expenses, depreciation, and interest costs without contributing to the top or bottom line. Management expects a sizable revenue contribution from this segment to commence from Q4 FY26 or Q1 FY27. This project, along with other planned expansions, is anticipated to be a key driver for growth from FY27 onwards, aligning with the company's strategy for sustainable expansion.

    06

    CPVC Market Dynamics and Pricing

    The CPVC market is currently at a bottom, with prices dropping by approximately 10% QoQ in Q2 FY26, influenced by the decline in PVC prices over the last year. Capacity utilization for CPVC was around 50% in both Q1 and Q2 FY26. Management believes that any anti-dumping duty on PVC could lead to an increase in PVC prices, which would subsequently impact CPVC prices positively, albeit with a lag of three to four months, with recovery expected from Q4 FY26 onwards.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.